NDUFA8: A Potential Drug Target and Biomarker (G4702)

Target Name: NDUFA8

NCBI ID: G4702

NDUFA8: A Potential Drug Target and Biomarker

The human body is equipped with a vast array of genetic mechanisms that work together to maintain proper cellular function. One of these mechanisms is the NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 8 (NDUFA8), which plays a crucial role in the production of NADH, a critical coenzyme that is essential for many cellular processes. NADH is a molecule that has been linked to a wide range of health benefits, including energy production, tissue repair, and immune function.

The NDUFA8 enzyme is a subunit of the ubiquinone coenzyme system, which is a network of proteins that work together to convert NADPH, a molecule that is involved in the production of energy, into NADH. NADH is then used by the cells to produce energy through the process of cellular respiration.

NDUFA8 is a protein that is expressed in many different tissues and cells throughout the body. It is found in the mitochondria, the endoplasmic reticulum, and the cytoplasm. NDUFA8 is also known to be involved in the production of other molecules, including superoxide, a molecule that can cause damage to cells and contribute to the aging process.

In recent years, researchers have become increasingly interested in NDUFA8 as a potential drug target and biomarker. This is because of the wide range of health benefits that have been associated with NADH and its production. For example, NADH has been linked to reduced risk of heart disease, neurodegenerative diseases, and certain types of cancer.

One of the key advantages of NDUFA8 as a potential drug target is its location in the ubiquinone coenzyme system. This system is a well-established target for drug developers because it is involved in a wide range of cellular processes that are important for human health. By targeting NDUFA8, researchers can potentially interfere with the production of NADH and other molecules that are involved in the ubiquinone system.

Another potential advantage of NDUFA8 is its role in the production of superoxide, a molecule that can cause damage to cells and contribute to the aging process. Superoxide is a free radical that can react with other free radicals (unstable, reactive molecules) and form a cascade of reactions that can cause damage to cells and contribute to the aging process.

Research has shown that NDUFA8 is involved in the production of superoxide, and that its activity in this process may be important for the aging process. For example, studies have shown that NDUFA8 levels are decreased in old mice compared to young mice, and that this decrease in NDUFA8 levels is associated with an increase in the production of superoxide.

In addition to its role in the production of superoxide, NDUFA8 may also be involved in the production of other molecules that are important for cellular function. For example, it has been shown to be involved in the production of certain signaling molecules, such as p53 , a protein that is involved in the regulation of cell growth and division.

The potential implications of NDUFA8 as a drug target and biomarker are significant. If NDUFA8 can be successfully targeted, it may be used to treat a wide range of conditions that are associated with the production of NADH or the production of superoxide. For example, it may be used to treat heart disease, neurodegenerative diseases, and certain types of cancer.

In addition to its potential therapeutic applications, NDUFA8 may also be used as a biomarker to diagnose and monitor certain types of diseases. For example, NDUFA8 levels may be used to diagnose

Protein Name: NADH:ubiquinone Oxidoreductase Subunit A8

Functions: Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis (PubMed:27626371, PubMed:32385911, PubMed:33153867). Complex I functions in the transfer of electrons from NADH to the respiratory chain (PubMed:27626371). The immediate electron acceptor for the enzyme is believed to be ubiquinone (PubMed:27626371)

More Common Targets